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Sixty-six 20- to 23-amino-acid synthetic peptides, partially overlapping by 10–12 amino acids, spanning the entire sequence
of the envelope SU and TM glycoproteins of the Petaluma isolate of FIV, have been used to investigate the Env domains
involved in viral infection. Peptides 5 to 7, spanning amino acids 225E–P264 located in a conserved region of the SU protein,
and peptides 58 to 61, spanning amino acids 757N–P806 and encompassing hypervariable region 8 of TM protein, exhibited
a remarkable and specific antiviral effect against the homologous and one heterologous isolate, as judged by inhibition of
FIV-induced syncytium formation and p25 production in CrFK cells. Peptides 5 and 7, but not peptides 58 and 59, also
inhibited viral replication of a fresh FIV isolate on nontransformed lymphoid cells. By flow cytometry, peptides 5, 7, 58, and
59 were shown to bind the surface of FIV permissive cells. The antiviral activity of peptides 5 and 7, however, was time-
dependent, as inhibition of FIV replication was seen when the peptides were administered before or within 3 hr after virus
inoculation; in contrast, TM peptides 58 and 59 exerted a potent inhibitory effect when added up to 24 hr after virus
inoculation. Circular dychroism analysis showed that peptide 5 folds to a helical conformation in the presence of a hydropho-
bic environment. Although the basis for the antiviral action of the peptides is not understood, our data suggest that the
inhibitory peptides may act by interacting with cell-surface molecules involved in viral infection. q 1996 Academic Press, Inc.
INTRODUCTION phocytes and FIV-infected cats show a marked reduction
of circulating CD4/ T lymphocytes (Ackley et al., 1990b;
Feline immunodeficiency virus (FIV) is a widespread
Brown et al., 1991); cells of the monocyte–macrophage–
lentivirus of domestic cats sharing numerous biological
microglia lineage and astrocytes are also infected in vitro
and pathogenetic features with the human immunodefi- (Brunner and Pedersen, 1989; Dow et al., 1992; Pedersen,
ciency virus (HIV). FIV infection in cats has therefore 1993). Despite these similarities, which led to the initial
been proposed as an animal model for AIDS studies with suggestion that, as for HIV, the feline CD4 (fCD4) antigen
respect to pathogenesis, chemotherapy, and vaccine de- might be the cellular receptor for FIV, there is a lack of
velopment (Pedersen, 1993; Bendinelli et al., 1995). correlation between the expression of fCD4 on cells and
Similar to HIV and other lentiviruses, the FIV envelope their ability to support FIV replication (Brown et al., 1991).
(Env) surface protein (SU) gp95 and the transmembrane Furthermore, fCD4 expression is restricted to a subpopu-
protein (TM) gp40, encoded by the env gene, appear to lation of T lymphocytes and its thymic precursor, and it
play a pivotal role in the early steps necessary for virus is unlikely that the fCD4 molecule alone could account
entry into cells and, as a consequence, are regarded for the relatively broad cell tropism of FIV (Ackley et al.,
as the primary targets of a putative protective immune 1990a). Recently, a putative non-CD4 receptor has been
response. The env gene shows sequence diversities identified by means of a cell-specific monoclonal anti-
among different FIV isolates that cluster in discrete seg- body, named vpg15, that efficiently blocks FIV infection
ments known as hypervariable (V) regions. Eight or possi- of susceptible cells in vitro but is unable to bind the virus
bly nine such V regions have been identified (Phillips et (Hosie et al., 1993). This antibody recognizes a 24-kDa
al., 1990; Morikawa et al., 1991; Rigby et al., 1993; Pan- cell-surface protein on feline cells identified as the feline
cino et al., 1993). homolog of human CD9, a marker expressed on a range
The interactions between FIV and susceptible cells of cell types of both hematopoietic and nonhematopoietic
are poorly understood. Similar to HIV, FIV infects T lym- origin (Willet et al., 1994); it has yet to be established,
however, whether feline CD9 is a primary binding recep-
tor for FIV or a molecule necessary for a subsequent1 To whom correspondence should be addressed at Department of
step in viral entry (Willett and Neil, 1995). On the otherBiomedicine, Via S. Zeno, 35/39, 56127 Pisa, Italy. Fax: /50-555477.
E-mail: garzelli@biomed.unipi.it. hand, no information is available on the SU and/or TM
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domains involved in FIV binding to target cells nor on fibroblasts from SPF cat skin biopsy (275 cells) were
maintained as monolayer cultures in Dulbecco’s modifiedthe other physiological events underlying virus attach-
ment and penetration. minimum essential medium supplemented as above.
A suitable system for studying in vitro interactions be-
Synthetic peptidestween FIV Env domains and target cell molecules is rep-
resented by the Crandell feline kidney (CrFK) fibro- On the basis of the published sequence of the
blastoid cell line and the Petaluma isolate of FIV (FIV- 34TF10 clone of FIV-Pet (Talbot et al., 1989), sixty-six
Pet). Four to 6 days after infection with FIV-Pet, these 20- to 23-amino-acid peptides, partially overlapping by
cells develop large syncytia and produce infectious virus 10 – 12 amino acids (see Table 1) and covering the
detectable as p25 antigen in the culture supernatant entire SU and TM proteins of the FIV env region, were
(Tozzini et al., 1992, 1993; Lombardi et al., 1994). In this manually synthesized using N-a-fluorenylmethoxycar-
study we have synthesized sixty-six 20- to 23-amino-acid bonyl (FMOC)-protected amino acids and a p-alkoxy-
peptides, partially overlapping by 10–12 amino acids and benzyl alcohol resin as solid phase, as previously de-
spanning the entire deduced sequences of the SU and scribed (Lombardi et al., 1993).
TM proteins of FIV-Pet, and examined their ability to in- Peptides 5, 7, and 59 were also prepared by continu-
hibit FIV-induced syncytium formation and p25 produc- ous-flow solid-phase peptide synthesis using conven-
tion. This has led to the identification of two linear do- tional FMOC strategy on a Milligen 9050 automatic syn-
mains located, respectively, on the SU and TM envelope thesizer and purified to homogeneity by preparative re-
glycoproteins that markedly inhibit cell infection by FIV verse-phase high-pressure liquid chromatography
in vitro. (HPLC). The identity of the final products, whose HPLC
purity was greater than 97%, was verified by electrospray
MATERIALS AND METHODS mass spectrometry.
Viruses Peptide inhibition of syncytium formation
Two different FIV isolates, i.e., the California isolate Peptides were screened for the capability to inhibit
Petaluma (FIV-Pet), kindly provided by Dr. J. Yamamoto FIV replication using an assay based on FIV-induced
(Yamamoto et al., 1988, 1991), and the local isolate Pisa- syncytium formation (Tozzini et al., 1992). Briefly, solu-
M2 (FIV-M2) (Baldinotti et al., 1994), have been used. The tions of peptides were added at the final concentration
FIV-M2 isolate was originally obtained from a clinically of 16 mg/ml (unless otherwise stated) to 2 1 104 CrFK
healthy feline leukemia virus (FeLV)-negative cat and cells in 0.8 ml of culture medium containing 0.5% FBS in
freed of the feline syncytium-forming spumavirus 24-well plates; unless otherwise stated, after 1 hr at 377C
(FeSFV), which was initially present. Unless otherwise approximately 50–100 syncytium-forming units (SFU) of
stated, viruses were propagated in CrFK cells as pre- FIV-Pet or, in some experiments, FIV-M2 or FeSFV were
viously described (Tozzini et al., 1992). In experiments added in 0.2 ml volume. Six days later, the cultures were
employing MBM cells (see below), a fresh FIV-M2 isolate stained and the number of syncytia was counted under
was propagated in and harvested from MBM cells, as the microscope.
previously described (Baldinotti et al., 1994). In some
experiments, a local isolate of FeSFV, identified by neu- Capture ELISA for p25 antigen
tralization and immunofluorescence assays with sera
FIV p25 core antigen was assayed by capture ELISAkindly provided by Dr. N. C. Pedersen and propagated
as previously described (Lombardi et al., 1994). Briefly,in CrFK cells, was also used.
plates (Probind, Falcon, Italy) were coated overnight with
0.5 mg purified AE11 MAb in 100 ml carbonate buffer, pHCell lines and culture conditions
9.6. After four washes with PBS containing 0.05% Tween
20 (PBS–Tw), plates were postcoated with 150 ml of PBSCrFK cells were grown in Eagle’s minimal essential
medium supplemented with 0.5% fetal bovine serum containing 1% bovine serum albumin (BSA) (PBS–BSA)
for 1 hr. Test samples (100 ml) containing 0.5% Triton X-(FBS) and additional supplement (Tozzini et al., 1992).
The human erythroleukemia K562 cells, human histio- 100 were added to the wells and incubated for 2 hr. After
four washes, 0.1 mg biotin-conjugated DF10 MAb in 100cytic lymphoma U-937 cells, and the interleukin 2- and
concanavalin A-dependent, CD4-negative feline T-cell ml of PBS containing 1% skim milk, 5% fetal calf serum,
and 0.05% Tween 20 (dilution buffer) was added andline MBM, established from the peripheral blood mono-
nuclear cells (PBMC) of an FIV- and FeLV-negative SPF incubated for 1 hr. The plates were then washed and
further incubated for 1 hr with 100 ml of a horseradishcat (Matteucci et al., 1995), were maintained as suspen-
sion cultures in RPMI 1640 medium supplemented with peroxidase (HPRO)-conjugated anti-biotin (Sigma, St.
Louis, MO) diluted 1:1000 in PBS–Tw–BSA. The enzyme10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100
mg/ml streptomycin. Murine 3T3 fibroblasts and primary reaction was carried out with 100 ml tetramethylbenzidine
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TABLE 1
Amino Acid Sequence of the FIV Env Synthetic Peptides Used
Peptide Peptide
No. Sequencea No. Sequence
1 181PPLVVPVEESEIIFWDCWAPEE202 34 517FNMTKAVEMVNIAGNWSCTS536
2 193IFWDCWAPEEPACQDFLGAMIH214 35 527NIAGNWSCTSDLPSSWGYMN546
3 203PACQDFLGAMIHLKAKTNISIR224 36 534CTSDLPSSWGYMNCNCTNSSSS555
4 215LKAKTNISIREGPTLGNWAR234 37 547CNCTNSSSSYSGTKMACPSNRG568
5 225EGPTLGNWAREIWATLFKKA244 38 557SGTKMACPSNRGILRNWYNP576
6 235EIWATLFKKATRQCRRGRIW254 39 567RGILRNWYNPFAGLRQSLEQ586
7 245TRQCRRGRIWKRWNETITGP264 40 577VAGLRQSLEQYQVVKQPDYL596
8 255KRWNETITGPSGCANNTCYN274 41 587YQVVKQPDYLLVPEEVMEYK606
9 265SGCANNTCYNVSVIVPDYQC284 42 593PDYLLVPEEVMEYKPRRKRAAI614
10 275VSVIVPDYQCYLDRVDTWLQ294 43 605YKPRRKRAAIHVMLALATVLSI626
11 285YLDRVDTWLQGKINISLCLT304 44 615HVMLALATVLSIAGAGTGATAI636
12 295GKINISLCLTGGKMLYNKVT314 45 627AGAGTGATAIGMVTQYHQVL646
13 305GGKMLYNKVTKQLSYCTDPL324 46 637GMVTQYHQVLATHQEAIEKV656
14 315KQLSYCTDPLQIPLINYTFG334 47 647ATHQEAIEKVTGALKINNLR666
15 325QIPLINYTFGPNQTCMWNTS344 48 657TGALKINNLRLVTLEHQVLV676
16 335PNQTCMWNTSQIQDPEIPKC354 49 667LVTLEHQVLVIGLKVEAMEK686
17 345QIQDPEIPKCGWWNQMAYYN364 50 677IGLKVEAMEKFLYTAFAMQE696
18 355GWWNQMAYYNSCKWEEAKVK374 51 687FLYTAFAMQELGCNQNQFFC706
19 366CKWEEAKVKFHCQRTQSQPGSW387 52 697LGCNQNQFFCKIPLELWTRY716
20 375FHCQRTQSQPGSWFRAISSWKQ396 53 707KIPLELWTRYNMTINQTIWN726
21 385GSWFRAISSWKQRNRWEWRPDF406 54 717NMTINQTIWNHGNITLGEWY736
22 395KQRNRWEWRPDFKSKKVKISLPC417 55 727HGNITLGEWYNQTKDLQQKF746
23 407KSKKVKISLPCNSTKNLTFA426 56 737NQTKDLQQKFYEIIMDIEQN756
24 417CNSTKNLTFAMRSSGDYGEV436 57 747YEIIMDIEQNNVQGKTGIQQ766
25 427MRSSGDYGEVTGAWIEFGCH446 58 757NVQGKTGIQQLQKWEDWVRW776
26 437TGAWIEFGCHRNKSNLHTEA456 59 767LQKWEDWVRWIGNIPQYLKG786
27 447RNKSNLHTEARFRIRCRWNV466 60 777IGNIPQYLKGLLGGILGIGL796
28 457RFRIRCRWNVGSDTSLIDTC476 61 787LLGGILGIGLGVLLLILCLP806
29 467GSDTSLIDTCGNTPNVSGAN486 62 797GVLLLILCLPTLVDCIRNCI816
30 477GNTPNVSGANPVDCTMYSNK496 63 807TLVDCIRNCIHKILGYTVIA826
31 487PVDCTMYSNKMYNCSLQNGF506 64 817HKILGYTVIAMPEVEGEEIQ836
32 497MYNCSLQNGFTMKVDDLIVH516 65 827MPEVEGEEIQPQMELRRNGR846
33 507TMKVDDLIVHFNMTKAVEMV526 66 837PQMELRRNGRQCGMSEKEEE856
a Deduced from the 34TF10 clone of FIV-Pet (Talbot et al., 1989).
(KPL, Gaithersburg, MD) and stopped with 50 ml 0.1 N conjugated peptide at the final concentration of 10 mg/
ml in a 100-ml volume of PBS containing 1% BSA. AfterH2SO4 ; the absorbance was measured at 450 nm. All
steps were performed at RT. Duplicate wells containing two further washings, cells were fixed in PBS containing
1% p-formaldehyde, 1% BSA, and 0.1% sodium azide.twofold dilutions of recombinant p25 (kindly provided by
Dr. O. Jarrett) ranging from 500 to 0.03 ng/ml served for Flow cytometry analysis was performed with an Epics
Elite cell analyzer (Coulter Electronics, Hialeah, FL)standard curve.
equipped with an air-cooled argon laser operating at 15
FITC-labeling of peptides mW and 488-nm line emission. Viable cells were gated
One milliliter of peptide solutions in 0.1 M Na2CO3 , in a two-parameter histogram of size versus granularity
pH 9.0 (1.5 mg/ml), was mixed with 50 ml of fluorescein and approximately 10,000 cells were collected in each
isothiocyanate (FITC, Sigma) diluted at 1 mg/ml in di- fluorescence histogram, as previously described (Lom-
methyl sulfoxide and incubated overnight at 47C. NH4Cl bardi et al., 1994).
(50 mM final concentration) was added and further in-
cubated at 47C for 2 hr. The peptides were then freed Circular dichroism (CD) measurements
of unbound FITC by passing through a Sephadex G-
CD spectra were recorded at 257C on a Jasco J500A25 column.
spectropolarimeter in 10 mM sodium phosphate buffer,
Flow cytometry pH 7.0l, containing 150 mM NaCl or in the same buffer
in the presence of 90% methanol (v/v) or 40 mM sodiumCells (2 1 105), washed twice with PBS containing 1%
BSA, were incubated for 30 min at 47C with fluorescein- dodecyl sulfate (SDS). Data are expressed as molar ellip-
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ticity [U] (deg cm2 dmol01), based on the mean residue
molecular weight.
RESULTS
Screening of Env peptides for inhibition of FIV-
induced syncytium formation
Previous studies have shown that inhibition of syncy-
tium formation in CrFK cells is a useful screening method
for detecting substances that block FIV infectivity, such
as broadly reactive neutralizing antibodies (Tozzini et al.,
1993). In a first group of experiments the 66 partially
overlapping synthetic peptides covering the entire Env
glycoproteins of FIV were screened for the capacity to
affect FIV replication by using this approach. To this pur-
pose, each peptide was added to CrFK cells in 24-well
plates and after 1 hr at 377C the cultures were inoculated
with 50–100 SFU of FIV-Pet. FIV-induced syncytia were
counted 6 days later. Figure 1 summarizes the results
from numerous experiments in which each peptide was
tested at least three times. In spite of a certain degree
of variation in different experiments, the peptides corre-
sponding to two specific domains of the Env proteins
exhibited a remarkable and highly reproducible antiviral
effect, reducing syncytium formation by over 90% in all
the experiments. One such domain, represented by pep-
tides 5, 6, and 7, is located in the conserved near-amino-
terminal portion of the SU protein spanning amino acids
225E–P264. The second domain, represented by peptides
58, 59, 60, and 61, is located in the external portion of
the TM protein adjoining the transmembrane region,
spanning amino acids 757N –P806, and encompasses a
segment that presents a considerable degree of se-
FIG. 1. Inhibition of FIV-induced syncytium formation by 66 syntheticquence variation, known as hypervariable region 8 (Phil-
peptides covering the entire SU and TM proteins of FIV. Peptides atlips et al., 1990; Morikawa et al., 1991; Rigby et al., 1993;
16 mg/ml (final concentration) were incubated for 1 hr with CrFK cells
Pancino et al., 1993). Peptides derived from a third region, that were then infected with 50–100 SFU of FIV-Pet adapted to grow
located around the cleavage site of the SU and TM pro- in these cells. Syncytia were counted 6 days later. The inhibition values
reported represent the arithmetic means of the inhibition values ob-teins, were also inhibitory (peptides 38 to 50), but the
served for each peptide in at least three independent experiments. Thereduction of syncytium formation produced seldom ex-
location of the synthetic peptides on the Env sequence is indicatedceeded 60%. Inhibition levels lower than 30% were not
along the x-axis together with the location of hypervariable (V) regions.
considered of interest. Peptide 19, spanning amino acids Arrow indicates the splicing site between surface (SU) and transmem-
367C–W387 and located in FIV V3 loop, exerted an enhanc- brane (TM) glycoproteins; numbers above the continuos horizontal line
show the amino acid positions in the env gene product. As the peptidesing effect on syncytium production (unpublished observa-
overlapped one another in such a way as to reproduce the Env proteinstions). A similar enhancement of infection has been re-
twice, the results obtained with the even and odd peptides are shownported for HIV-1 V3 loop synthetic peptides (Zanotto et
in separate panels to better locate peptide activities on the Env protein
al., 1995). sequences.
Although we cannot exclude that the assay we used
may miss some inhibitory peptide, on the basis of the
the ability to block FIV replication by measuring thefindings reported above, we selected peptides 5, 7, 58,
amount of p25 released in the supernatant fluids of in-and 59 for further studies. Peptide 66 and occasionally
fected cultures. They were first tested against FIV-Pet inpeptides 36 and 54 were used as a noninhibitory nega-
CrFK cells. As shown in the experiment depicted in Fig.tive controls.
2, peptides 5, 7, 58, and 59 reduced syncytium formation
Inhibition of FIV replication in CrFK and MBM cells by and p25 antigen production in a dose-dependent man-
selected Env peptides ner. The lowest concentrations of peptide required to
reduce by 50% the amount of p25 antigen producedThe peptides that had proven potent inhibitors of FIV-
induced syncytium formation were examined directly for ranged between 1 mg/ml (peptides 58 and 59) and 8 mg/
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FIG. 2. Dose dependence of inhibition of FIV-induced syncytium formation and p25 production by selected Env peptides in CrFK cells. Peptides
were incubated at final concentrations ranging from 0.25 to 16 mg/ml for 1 hr with CrFK cells that were then infected with 50–100 SFU of FIV-Pet
adapted to grow in these cells. Syncytia (j) and p25 levels (h) were counted 6 days later; bars represent the mean { 1 SD of duplicate cultures
(some error bars are smaller than the markers and do not appear in the figure). Horizontal dashed and dotted–dashed lines represent the mean
numbers of syncytia and p25 levels, respectively, in the absence of peptide of triplicate cultures; SD were 3.2 and 2.7, respectively (not shown).
Peptide 66 (negative control) did not affect the numbers of syncytia and p25 level at all tested doses (data not shown).
ml (peptide 7). In the experiment shown in Fig. 2 the tested peptides 5, 7, 58, and 59 for the ability to inhibit
a fresh isolate of FIV. The virus used was an early pas-peptides also determined an increase in p25 levels at
low concentrations; the magnitude of this effect, how- sage of FIV-M2 that had been propagated in vitro only 6
times and solely in nontransformed lymphoid cells, andever, varied considerably in different experiments.
Additional studies performed with the local isolate FIV- the cell type used as substrate was the T lymphocyte
cell line MBM. Previous work has shown that the targetM2 adapted to CrFK cells gave similar overall results,
thus showing that the blocking activity of the peptides is cell used may also affect the results of FIV blocking
experiments (Baldinotti et al., 1994). MBM cells were cul-not restricted to the homologous viral isolate after which
the peptides were modeled (namely FIV-Pet), but ex- tured at 5 1 104 cells per well in 96-well microplates in
the presence of varying concentrations of the peptidestended to a heterologous virus (data not shown; see also
Table 3). FIV-Pet and FIV-M2 show considerable genetic and, after 1 hr at 377C, 10 TCID50 of FIV-M2 were added
to each well. The amounts of p25 antigen released indiversity and have been classified in different clades
(clades A and B, respectively) based on partial gag and the culture supernatants were measured 4, 8, and 12
days later. Each peptide was tested at least twice inenv gene sequences (Cammarota et al., 1996).
The FIV isolates used in the previous experiments quadruplicate. The results showed that SU peptides 5
and 7 were also active in this infection system, thoughwere laboratory strains adapted to grow in CrFK cells
and had been passaged in vitro 234 (FIV-Pet) and 18 less efficiently than in the CrFK system. At concentrations
of 1 and 2.5 mg/ml they had no detectable effects on FIV-times (FIV-M2). Since prolonged growth in vitro has been
shown to significantly modify several properties of lentivi- M2 replication and at 5 mg/ml inhibited virus replication
by approximately 50% and with a certain variability inruses including sensitivity to blocking agents such as
neutralizing antibody and soluble receptor (Baldinotti et different experiments (data not shown). At 10 mg/ml (see
Table 2), these peptides significantly inhibited FIV repli-al., 1994; Golding et al., 1994; Moore et al., 1995), we
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TABLE 2 Effect of varying the timing of FIV-inhibitory peptide
administrationEffect of Selected Env Peptides on FIV-M2 Replication
in MBM Cells In these experiments, CrFK cells grown in 24-well
plates were mixed with approximately 100 SFU of FIV-Day of culture
Pet and 1, 3, 8, and 24 hr later treated with peptides 5, 7,Exp
No. Peptidea 4 8 12 58, or 59. Positive controls consisted of cultures receiving
peptides 1 hr before virus; negative control cultures re-
1 None 18 { 2b 51 { 18 250 ceived no peptides or peptide 66 at all tested times.
54 (0ctrl) 20 { 1 75 { 9 250
After 6 days incubation, 2 wells for each peptide/timing36 (0ctrl) 20 { 3 60 { 14 250
combination were examined for FIV-induced syncytia and5 15 { 1* 26 { 8* 245 { 10
7 13 { 1* 15 { 7* 154 { 65* p25 content in the supernatant fluids. As shown in Fig.
59 19 { 1 59 { 14 250 3, peptides 5, 7, 58, and 59, as expected, determined a
2 None 23 { 1 54 { 16 246 { 5 marked inhibition of both syncytium formation and p25
66 (0ctrl) 24 { 1 ND 184 { 105
release when added to the cultures 1 hr before virus5 21 { 3 36 { 15 62 { 34*
infection. Moreover, the addition of peptide 59 exerted7 15 { 1* 6 { 3* 32 { 14*
58 21 { 2 37 { 14 230 { 28 the most powerful inhibitory effect, virtually preventing
syncytium formation and p25 antigen production at all
Note. ND, not determined. the times tested after FIV infection within the 24 hr stud-a Peptides were tested at the final concentration of 10 mg/ml.
ied. FIV inhibition by peptide 58 was also affected littleb Data expressed as mean { SD ng/ml of p25 in quadruplicate cul-
by varying the time of posttreatment and was visible onture supernatants.
* P  0.05, according to Student’s t test, when compared to control both syncytium formation and p25 antigen production but
cultures in the absence of peptide. was much less pronounced than in the experiments in
which the same peptide was added before the cells were
exposed to the virus. In contrast, peptides 5 and 7 seem
cation although with some scatter in different experi- more time-dependent in their action, producing a clear-
ments. In contrast, peptides 58 and 59 failed to demon- cut reduction of the numbers of syncytia produced only
strate an antiviral effect. As expected, negative control when added within 1 and 3 hr after virus inoculation,
peptides 36, 54, and 66 exhibited no inhibitory activity. respectively; on the other hand, the levels of p25 pro-
duced were appreciably reduced only by peptide 7 added
within 3 hr postinfection. FIV absorption to CrFK cellsSpecificity of the anti-FIV activity of Env peptides
can be considered complete by this time (Tozzini et al.,
1992). When peptides were added 8 or 24 hr postinfec-At the concentrations used, the FIV-inhibitory peptides
tion we observed a slight reduction of numbers of syncy-exerted no overt effects on CrFK or MBM cell growth or
tia, but the levels of p25 were not significantly affected.morphology, thus excluding that inhibition of FIV replica-
tion was a mere consequence of peptide cytotoxicity or
Binding of FIV-inhibitory Env peptides to substrate
cytostasis. To exclude that the inhibitory effects were
cells
due to impurities or unwanted peptides present in the
synthetic peptide preparations, new batches of peptides To investigate whether inhibition of FIV replication corre-
5, 7, and 59 were synthesized and highly purified, and the lated with Env peptide binding to substrate cells, CrFK and
identity of the final products was verified by electrospray MBM cells were examined for the ability to bind peptides 5,
mass spectrometry. The newly synthesized peptides in- 7, 58, 59, and 66 (negative control). As judged from the
hibited FIV replication and syncytium formation as effec- proportion of fluorescent cells observed by flow cytometry
tively as the original batches (data not shown). In addi- following incubation with FITC-labeled peptides at 47C for
tional experiments, peptides 5, 7, 58, 59, and 66 (negative 30 min, peptides 5, 7, and 59 were bound effectively by both
control) were examined for the ability to affect syncytium CrFK and MBM cells while peptide 58 was bound by CrFK
production in CrFK cells by an unrelated feline retrovirus, cells only and peptide 66 was not bound by either cell type.
FeSFV. Table 3 shows the results of one representative Interestingly, a similar binding pattern was observed with
experiment. In the presence of the FIV-inhibitory peptides two other cell types that are permissive for FIV replication
added to the cultures 1 hr prior to virus inoculation, and express the putative FIV receptor recognized by mono-
FeSFV produced numbers of syncytia similar to those clonal antibody vpg15, namely fresh feline PBMC and pri-
produced in the absence of peptides or in the presence mary feline lymphoblasts obtained by stimulating PBMC with
of negative control peptides. Consistent with previous Con A for 3 days (PBMC–Con A), whereas several FIV-
results, in the same experiment FIV-Pet and FIV-M2 un- nonpermissive cells failed to bind the peptides. The latter
derwent the expected degrees of peptide-mediated inhi- cells included primary feline fibroblasts that expressed the
vpg15 antigen but did not replicate FIV to any detectablebition (Table 3).
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TABLE 3
Effect of Selected Env Peptides on FIV and FeSFV Infection of Feline CrFK
FIV-Pet FIV-M2 FeSFV
No. of p25 No. of p25 No. of
Peptide syncytia (ng/ml) syncytia (ng/ml) syncytia
None 57 { 4 85 { 6 28 { 2 350 { 45 118 { 3
66 (0ctrl) 54 { 4 78 { 7 23 { 7 300 { 30 124 { 12
5 1 { 1 0 2 { 1 20 { 10 109 { 14
7 4 { 3 5 { 2 1 { 1 62 { 10 104 { 7
58 0 9 { 1 0 103 { 25 101 { 8
59 0 0 0 0 111 { 10
61 2 { 1 14 { 7 0 38 { 3 112 { 11
Note. CrFK cells were infected with approximately 50, 25, and 100 SFU of FIV-Pet, FIV-M2, and FeSFV, respectively. Numbers of syncytia and
levels of p25 produced were evaluated after 6 days of culture and expressed as mean { SD of triplicate cultures.
extent (unpublished observation), as well as the murine cell CD analysis of selected peptides
line 3T3, fresh human PBMC, and the human cell line K562,
Peptides 5, 7, 58, and 59 were analyzed by circularwhich were all vpg15 negative. However, the human cell
dichroism under various solution conditions. CD spectraline U937, which is also vpg15 negative, bound peptides 7
and 59 at least as effectively as CrFK cells (Table 4). of peptides 7, 58, and 59 indicate that the peptides adopt
FIG. 3. FIV-induced syncytium formation and p25 production in CrFK cells treated with selected Env peptides at various times after FIV infection.
CrFK cells were infected with approximately 100 SFU of FIV-Pet adapted to grow in these cells and 1, 3, 8, and 24 hr later treated with peptides
at the final concentration of 16 mg/ml. Inhibition control cultures received peptides 1 hr before virus (time  01). Syncytia (j) and p25 levels (h)
were counted 6 days later; bars represent the mean { 1 SD of duplicate cultures. Horizontal dashed and dotted–dashed lines represent the mean
numbers of syncytia and p25 levels, respectively, in the absence of peptide of triplicate cultures; SD were 1.7 and 2.5, respectively (not shown).
Peptide 66 (negative control) did not affect the number of syncytia and p25 levels at all tested times (data not shown).
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TABLE 4
Binding of Selected Env Peptides to Different Cell Types
Percentage of positive cellsa
Peptide
66 Antibody
Cells Type (0ctrl) 5 7 58 59 vpg15
CrFK Cat fibrolastoid kidney line 1.5 32 49 26 30 100
MBM Cat T-cell line 0.8 39 43 0.0 35 100
fPBL Primary cat PBMC 1.5 29 10 4 14 50
fPBL-Con A Con A-stimulated primary cat PBMC 1.2 25 5 3 21 45
275 Primary cat fibroblasts 0.3 0.2 0.3 0.1 0.1 100
hPBMC Primary human PBMC 0.0 0.0 0.0 0.0 0.0 ND
3T3 Mouse fibroblast line 0.1 0.6 0.0 0.3 0.5 0.5
U937 Human histiocytic lymphoma cell line 0.2 0.2 49 0.1 41 0.0
K562 Human chronic myeloid leukemia line 0.1 0.2 0.1 0.1 0.0 0.0
a Assessed by flow cytometry using FITC-labeled peptides.
random coil structure under all the conditions studied markedly in the presence of SDS, at concentrations
above its critical micelle concentration, or methanol(not shown). On the other hand, in 10 mM sodium phos-
phate buffer, pH 7.0l, containing 150 mM NaCl, the spec- (curves 2 and 3, respectively). Under these conditions
the spectra exhibited the two negative minima at 222trum of peptide 5 showed a weak band at about 220 nm
and a stronger negative band near 200 nm (Fig. 4, curve and 208 nm, typical of the a-helix structure. Assuming
[U]222  ca. 030,000 deg cm2 dmol01 for a 100% helical1), thus indicating that under these conditions peptide 5
also adopts an essentially random coil structure, as usu- structure containing 19 peptide chromophores at 257C
(Benson et al., 1995; Scholtz et al., 1991), the intensity ofally expected for short peptides. The weak band at 220
nm suggests the presence of a very small amount of the band at 222 nm, [U]222  011,000 deg cm2 dmol01,
corresponds to a helix content of about 35%; this sug-helical structure. The CD spectrum of peptide 5 changed
gests that approximately seven residues of the peptide
sequence form two a-helix turns.
DISCUSSION
In this first report investigating the effects of Env syn-
thetic peptides on FIV replication, peptides derived from
two regions of the env gene product of FIV-Pet were
found to exert a remarkable inhibitory action on CrFK cell
infection with the homologous and a heterologous FIV
isolate in vitro. The amino acid sequences involved span
residues 225E–P264 of the SU glycoprotein (peptides 5
through 7) and residues 757N–P806 of the TM molecule
(peptides 58 through 61). The inhibitions are apparently
specific for FIV, as the peptides proved unable to inhibit
infection of the same cell substrate with a different syncy-
tium-inducing retrovirus, i.e., FeSFV. The SU peptides, but
not the TM peptides, also inhibited infection of lymphoid
MBM cells by a fresh FIV isolate.
Antiviral activity of synthetic peptides deduced from
FIG. 4. Circular dichroism spectra of peptide 5 in 10 mM sodium Env glycoproteins has also been reported for HIV-1, in
phosphate buffer, pH 7.0l, containing 150 mM NaCl (curve 1) or in the which inhibitory domains have been mapped in the V3
same buffer in the presence of 40 mM SDS (curve 2) or 90% methanol principal neutralizing domain loop of gp120 and in the
(v/v) (curve 3). The spectra were found to be independent of peptide
ectodomain of gp41. In spite of structural and immuno-concentration in the range of 8 1 1002 to 8 1 1001 g/liter, thus showing
logical similarities between the V3 regions of HIV-1 andthat the peptide molecules are monomeric and do not aggregate in
solution. FIV (Lombardi et al., 1993), the peptides deduced from
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the FIV V3 loop, i.e., peptides 19 through 22, showed no may suggest that in proximity to cellular membrane,
where an apolar environment exists, peptide 5 may as-blocking activity, as well as no sequence homology with
the inhibitory peptides of HIV-1 V3. The inhibitory pep- sume a more stable secondary structure that might ac-
count for its antiviral and cell-surface binding activities.tides of FIV SU glycoprotein encompass a sequence that
is distant from V3 and that, according to an FIV Env In HIV-1, the inhibitory synthetic peptide DP107 exhibits,
under physiological conditions, an a-helix conformationglycoprotein structural model recently proposed (Pan-
cino et al., 1993), contains an a-helix structure. Moreover, characterized by a ‘‘leucine zipper-like motif,’’ a domain
probably involved in the infection event (Wild et al., 1992;this sequence is conserved among different FIV isolates
and seems not to be exposed on the surface of the SU Bernstein et al., 1995). Thus, the fact that peptides en-
dowed with an a-helix motif, although differently locatedmolecule as it forms a groove in the context of glycopro-
tein internal folding (Pancino et al., 1993). in the envelope glycoproteins of FIV and HIV-1, are able
to inhibit cell infection may indicate that the antiviral ac-The TM inhibitory sequence, corresponding to pep-
tides 58–61, is located in the external portion of the TM tivity of certain retroviral Env peptides depends on their
ability to accurately model functional viral protein do-glycoprotein adjoining the transmembrane region and
encloses, particularly with peptides 58 and 59, the whole mains.
The mechanism(s) whereby TM peptides 58 and 59domain V8, i.e., one of the three hypervariable regions
of the TM glycoprotein (Pancino et al., 1993). It is note- block FIV cell infection is not understood. In HIV-1, the
inhibitory peptides of gp41 seem to exert their antiviralworthy that in HIV-1 two partially overlapping synthetic
peptides, named DP178 (Wild et al., 1993, 1994) and activity by interacting with other regions of the gp41 mol-
ecule itself; in fact, a peptide of the gp41 ectodomain,SJ2176 (Neurath et al., 1995), which inhibit HIV-1 replica-
tion in vitro, are also localized near the membrane-span- coded DP-178 (Wild et al., 1995), interacts with the a-
helical structure exhibited by the above-mentioned pep-ning domain of the gp41 glycoprotein. This could suggest
that a domain of the external portion of the TM glycopro- tide DP-107 (Wild et al., 1992), thus causing the disruption
of the a-helical leucine zipper-like motif and inhibitingteins of lentiviruses, next to the viral envelope membrane,
plays an important role in cell infection. It is usually ac- HIV-1 cell infection. Another HIV-1 gp41 peptide, indi-
cated as SJ2176 (Jiang et al., 1993a,b; Neurath et al.,cepted that, irrespective of primary sequence, a common
general framework exists in the env gene products of 1995) and overlapping DP-178 (Neurath, et al., 1995),
shows selective binding to the N-terminal viral fusiondifferent lentiviruses (Gallaher et al., 1989, 1995; Schulz
et al., 1992; Pancino et al., 1993, 1994). domain of gp41 (Jiang et al., 1993b; Neurath et al., 1995);
this peptide seems to inhibit HIV-1 infection by pre-At this time, it is difficult to envision the mechanism(s)
by which SU and TM synthetic peptides block FIV replica- venting the interaction between the fusogenic domain
and relevant cell membrane constituents. Nevertheless,tion. In HIV-1, several different mechanisms have been
proposed to explain the inhibitory action of Env peptides; it has also been reported that another HIV-1 gp41 inhibi-
tory peptide, named CS3, blocks HIV entry into humanhowever, it is generally agreed that both gp41 and gp120
peptides interfere with cell infection at early steps neces- CD4/ cells by directly binding to two proteins of the cell
surface, respectively, of 45 and 80 kDa (Henderson andsary for virus entry into host cells (Wild et al., 1994; Jiang
et al., 1993a,b; Yahi et al., 1995a). In particular, it has Qureshi, 1993). In FIV, TM peptides 58 and 59, though
capable of binding FIV permissive cells, inhibit FIV infec-been reported that synthetic peptides of HIV-1 gp120
block cell infection by directly interacting with cell-sur- tion also when added after the virus. This might indicate
that TM peptides interfere with virus replication at a stepface molecules; in fact, peptides or polymeric constructs
derived from V3 bind CD4, the major HIV-1 receptor, and subsequent to virus absorption. Moreover, our data sug-
gest that FIV inhibition by these peptides might be depen-the non-CD4 receptor galactosylceramide and other po-
tential coreceptors (Benjouad et al., 1995; Yahi et al., dent on cell type and/or viral isolate. In CrFK cells they
exerted an antiviral activity against homologous and het-1994, 1995a,b). In the FIV model, SU peptides 5 and 7
bound the surface of FIV permissive cells and were erologous FIV isolates and gave 100% reduction of syncy-
tium formation at a concentration 10 times lower thanhighly active in blocking FIV infection when administered
before the virus, but were not active when added to cells SU peptides but, contrary to SU peptides, were inactive
when tested in lymphoid MBM cells infected with a fresha few hours after initial contact with the virus. This might
suggest that the SU peptides specifically interact with FIV isolate.
Finally, a common feature of SU and TM inhibitorycell-surface molecules involved in viral infection and
compete with FIV binding to cell receptor(s). Moreover, peptides of FIV is the lack of antigenic activity; we have
in fact observed that synthetic peptides 5, 7, 58, and 59CD analysis showed that peptide 5 is essentially random
coil under physiological conditions, but undergoes a are not recognized by sera of cats infected with FIV-
Pet or FIV-M2 and do not induce detectable humoralmarked conformational change and shows a significant
increase of the a-helix conformation upon going to more responses when repeatedly injected into mice (Massi et
al., manuscript in preparation). This should prove usefulhydrophobic environments, such as SDS micelles. This
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human immunodeficiency virus infection binds to a novel cell surfacein future studies, since antibody-mediated clearance will
polypeptide. J. Biol. Chem. 268, 15291–15297.not hinder evaluation of the peptides as anti-FIV agents
Hosie, M. J., Willet, B. J., Dunsford, T. H., Jarret, O., and Neil, J. C.
in vivo. Also, it is tempting to speculate that lack of immu- (1993). A monoclonal antibody which blocks infection with feline
nogenicity of critical segments of the Env molecules is immunodeficiency virus identifies a possible non-CD4 receptor. J.
Virol. 67, 1667–1671.yet another escape mechanism that protects the virus
Jiang, S., Lin, K., Stick, N., and Neurath, A. R. (1993a). HIV-1 inhibitionfrom a host’s immune response.
by a peptide. Nature 365, 113.
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